1. Kidman R, Breton E, Behrman J, Kohler HP, et al.
   A prospective study on adverse childhood experiences and HIV-related risk among adolescents in Malawi.
   AIDS 2022.
   


2. Phipps W, Adams SV, Mooka P, Kafeero J, et al.
   A prospective study of HIV-associated and hiv-negative kaposi sarcoma in Uganda: identifying factors associated with poor outcomes.
   AIDS 2022.
   


3. Ripamonti D, Poliseno M, Mazzola G, Colletti P, et al.
   Perceptions of U=U among Italian Infectious Diseases Specialists: a nationwide survey on providers' attitudes towards the risk of HIV transmission in virologically suppressed patients.
   AIDS Res Hum Retroviruses 2022.
   


4. Lantz A, Nicol MR.
   Translational Models to Predict Target Concentrations for Pre-Exposure Prophylaxis in Women.
   AIDS Res Hum Retroviruses 2022.
   


5. Kay A, Reyes JM, Devezin T, Bakaya M, et al.
   Optimal timing of antiretroviral therapy initiation in children and adolescents with HIV-associated pulmonary tuberculosis.
   Clin Infect Dis 2022.
   


6. McKinney J, Mirani G, Levison J.
   Providers have a responsibility to discuss options for infant feeding with pregnant people with HIV in high-income countries.
   Clin Infect Dis 2022.
   


7. Schoepf IC, Thorball CW, Kovari H, Ledergerber B, et al.
   Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons Living with HIV: The Swiss HIV Cohort Study.
   Clin Infect Dis 2022.
   


8. Ross J, Brazier E, Fatti G, Jaquet A, et al.
   Same-day ART initiation as a predictor of loss to follow-up and viral suppression among people living with HIV in sub-Saharan Africa.
   Clin Infect Dis 2022.
   


9. Feinstein MJ.
   HIV, Subclinical Cardiovascular Disease, and Clinical Progression: Insights From Immunologic Heterogeneity.
   JAMA 2022;328:931-932.
   


10. Hudson JA, Majonga ED, Ferrand RA, Perel P, et al.
    Association of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review.
    JAMA 2022;328:951-962.
    


11. Harris RM, Xavier Hall CD, Mills JC, Pence BW, et al.
    Beyond viral suppression - The impact of cumulative violence on health-related quality of life among a cohort of virally suppressed patients.
    J Acquir Immune Defic Syndr 2022.
    


12. Nyakato P, Christ B, Anderegg N, Muhairwe J, et al.
    High unreported mortality in children and youth (<25 years) living with HIV who were lost to care from antiretroviral therapy programs in Southern Africa: results from a multi-country tracing study.
    J Acquir Immune Defic Syndr 2022.
    


13. Zhong M, Chen C, Hu Y, Zou M, et al.
    Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China.
    J Acquir Immune Defic Syndr 2022;91:S42-S50.
    


14. Yan D, Wang Z, Wang Y, He S, et al.
    Performance of Creatinine- and Cystatin C-Based Equations for Glomerular Filtration Rate Estimation in HIV-1-Infected Individuals Receiving Dolutegravir + Tenofovir Disoproxil Fumarate + Lamivudine as Initial Antiretroviral Therapy: A Retrospective Ob
    J Acquir Immune Defic Syndr 2022;91:S35-S41.
    


15. Li CL, Liang HY, Xiao J, Li R, et al.
    The Effect of Pretreatment Potential Resistance to NNRTIs on Antiviral Therapy in Patients With HIV/AIDS.
    J Acquir Immune Defic Syndr 2022;91:S27-S34.
    


16. Nie J, Zeng Y, Zeng Q, Du X, et al.
    Risk Factors for CSF/Plasma HIV-1 RNA Discordance in HIV-Infected Patients.
    J Acquir Immune Defic Syndr 2022;91:S20-S26.
    


17. Zhao F, Rao M, Chen W, Cai K, et al.
    Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World.
    J Acquir Immune Defic Syndr 2022;91:S16-S19.
    


18. Sun L, He Y, Xu L, Zhao F, et al.
    Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
    J Acquir Immune Defic Syndr 2022;91:S8-S15.
    


19. Tongtong Y, Shenghua H, Yin W, Lin C, et al.
    Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
    J Acquir Immune Defic Syndr 2022;91:S1-S7.
    


20. Campbell CK, Ndukwe S, Dube K, Sauceda JA, et al.
    Overcoming Challenges of Online Research: Measures to Ensure Enrollment of Eligible Participants.
    J Acquir Immune Defic Syndr 2022;91:232-236.
    


21. Patil G, Mbewe EG, Kabundula PP, Smith H, et al.
    Longitudinal Cognitive Outcomes in Children With HIV in Zambia: 2-Year Outcomes From the HIV-Associated Neurocognitive Disorders in Zambia (HANDZ) Study.
    J Acquir Immune Defic Syndr 2022;91:217-225.
    


22. Geannopoulos K, McMahan C, Maldonado RS, Abbott A, et al.
    Retinal Thinning in People With Well-Controlled HIV Infection.
    J Acquir Immune Defic Syndr 2022;91:210-216.
    


23. Dumchev K, Kiriazova T, Riabokon S, Shost A, et al.
    Comparative Clinical Outcomes With Scale-up of Dolutegravir as First-Line Antiretroviral Therapy in Ukraine.
    J Acquir Immune Defic Syndr 2022;91:197-209.
    


24. Dorward J, Naidoo J, Moodley P, Sookrajh Y, et al.
    Diagnostic Accuracy of the Rapid Xpert HIV-1 Viral Load XC, Xpert HIV-1 Viral Load, & m-PIMA HIV-1/2 Viral Load in South African Clinics.
    J Acquir Immune Defic Syndr 2022;91:189-196.
    


25. Capparelli EV, Ajibola G, Maswabi K, Holme MP, et al.
    Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children.
    J Acquir Immune Defic Syndr 2022;91:182-188.
    


26. Lam JO, Leyden WA, Leong TK, Horberg MA, et al.
    Variation in Heart Failure Risk by HIV Severity and Sex in People With HIV Infection.
    J Acquir Immune Defic Syndr 2022;91:175-181.
    


27. Womack JA, Murphy TE, Leo-Summers L, Bates J, et al.
    Predictive Risk Model for Serious Falls Among Older Persons Living With HIV.
    J Acquir Immune Defic Syndr 2022;91:168-174.
    


28. Ross RD, Olali AZ, Shi Q, Hoover DR, et al.
    Brief Report: Undercarboxylated Osteocalcin Is Associated With Cognition in Women With and Without HIV.
    J Acquir Immune Defic Syndr 2022;91:162-167.
    


29. Czarnogorski M, Benn P, McCoig C, Nwafor T, et al.
    Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
    J Acquir Immune Defic Syndr 2022;91:157-161.
    


30. Goedel WC, Rogers BG, Li Y, Nunn AS, et al.
    Pre-exposure Prophylaxis Discontinuation During the COVID-19 Pandemic Among Men Who Have Sex With Men in a Multisite Clinical Cohort in the United States.
    J Acquir Immune Defic Syndr 2022;91:151-156.
    


31. Morgan E, Caba AE, Eaton LA, Watson RJ, et al.
    PrEP Access Affected by COVID-19 Is Associated With Increased Odds of HIV Seroconversion.
    J Acquir Immune Defic Syndr 2022;91:138-143.
    


32. Beesham I, Parikh UM, Mellors JW, Joseph Davey DL, et al.
    High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study.
    J Acquir Immune Defic Syndr 2022;91:130-137.
    


33. McClymont E, Faber MT, Lindquist S, Bone JN, et al.
    Human Papillomavirus Infection Among Pregnant Women Living With HIV: A Systematic Review and Meta-Analysis.
    J Acquir Immune Defic Syndr 2022;91:122-129.
    


34. Patel D, Williams WO, Wright C, Taylor-Aidoo N, et al.
    HIV Testing Services Outcomes in CDC-Funded Health Departments During COVID-19.
    J Acquir Immune Defic Syndr 2022;91:117-121.
    


35. Xia Q, Maduro GA, Li W, Huynh M, et al.
    Life expectancy among people with HIV in New York City, 2009-2018.
    J Acquir Immune Defic Syndr 2022.
    


36. Morris SR, Jain S, Blumenthal J, Bolan R, et al.
    Randomized Trial of Individualized Texting for Adherence Building (iTAB) plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study).
    J Acquir Immune Defic Syndr 2022.
    


37. Lechiile K, Leeme TB, Tenforde MW, Bapabi M, et al.
    Laboratory Evaluation of the VISITECT(R) Advanced Disease Semi-quantitative Point-of-care CD4 Test.
    J Acquir Immune Defic Syndr 2022.
    


38. Opsteen S, Moylan D, Taiwo BO, Robertson KR, et al.
    Intracellular cystatin B levels are altered in HIV-infected participants with respect to neurocognitive status and anti-retroviral therapy.
    J Acquir Immune Defic Syndr 2022.
    


39. Arens Y, Bilker WB, Han X, Plankey M, et al.
    HIV Infection Does Not Explain Higher Nicotine Metabolism in People Living with HIV.
    J Acquir Immune Defic Syndr 2022.
    


40. Drummond MB, Edmonds A, Ramirez C, Stosor V, et al.
    Association between HIV and prevalence and manifestations of asthma: Analysis of the Multicenter AIDS Cohort Study and Women's Interagency HIV Study.
    J Acquir Immune Defic Syndr 2022.
    


41. Campbell DM, Cowlings PD, Tholanah M, Robinson MJ, et al.
    "In diversity there is beauty and there is strength." -Dr. Maya Angelou A Community Call to Action to Prioritize Inclusion and Enrollment of Women in HIV Cure-Related Research.
    J Acquir Immune Defic Syndr 2022.
    


42. Peluso MJ, Mitchell A, Wang CY, Takahashi S, et al.
    Low Prevalence of Interferon-alpha Autoantibodies in People Experiencing Long COVID Symptoms.
    J Infect Dis 2022.
    


43. Margot NA, Naik V, VanderVeen L, Anoshchenko O, et al.
    Resistance analyses in Highly Treatment-Experienced People with HIV Treated with the Novel Capsid HIV Inhibitor Lenacapavir.
    J Infect Dis 2022.
    


44. Sapp N, Burge N, Cox K, Prakash P, et al.
    HIV-1 Preintegration Complex Preferentially Integrates the Viral DNA into Nucleosomes Containing Trimethylated Histone 3-Lysine 36 Modification and Flanking Linker DNA.
    J Virol 2022.
    


45. Anderson AS, Caubel P, Rusnak JM.
    Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
    N Engl J Med 2022.
    


46. Roehr B.
    Texas judge rules against ObamaCare coverage of HIV prevention drugs on religious grounds.
    BMJ 2022;378:o2213.
    


47. Martineau A.
    Behind the scenes at the Coronavit trial.
    BMJ 2022;378:o2203.
    

Display articles in

• Abstract format
• Medline format